STRATA

STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2023 Earnings

Retrieved on: 
水曜日, 3月 27, 2024
Growth, Webcast, Tax, International, Bank statement, Dermatology, DTC, Acne, Direct, Annual report, Report, Interest, Safety, SSKN, ID, Marketing, STRATA, Video game

Global recurring revenues for the fourth quarter of 2023 were $5.6 million, as compared to global recurring revenues of $6.5 million for the fourth quarter of 2022.

Key Points: 
  • Global recurring revenues for the fourth quarter of 2023 were $5.6 million, as compared to global recurring revenues of $6.5 million for the fourth quarter of 2022.
  • Equipment revenues were $3.1 million for the fourth quarter of 2023, as compared to $4.1 million for the fourth quarter of 2022.
  • Selling and marketing costs for the fourth quarter of 2023 were $2.8 million, as compared to $3.8 million for the fourth quarter of 2022.
  • Other expenses for the fourth quarter of 2023 were $0.4 million, compared to $0.2 million for the fourth quarter of 2022.

STRATA Skin Sciences Announces Initiative to Expand Treatment Coverage

Retrieved on: 
木曜日, 3月 7, 2024
Lichen planus, Light therapy, Assistant, Vitiligo, Marketing, Cutaneous T-cell lymphoma, Quality of life, Senate, Atopic dermatitis, Skin, CTCL, Mycosis fungoides, CPT, Human, Light, Alopecia areata, Patient, STRATA, SSKN, Insurance, Pharmaceutical industry

The Company is leveraging its extensive patient database and engaging in targeted governmental relations efforts, this initiative focuses on broadening Current Procedural Terminology (“CPT”) code coverage to increase patient access to advanced treatments and enable higher provider reimbursement rates.

Key Points: 
  • The Company is leveraging its extensive patient database and engaging in targeted governmental relations efforts, this initiative focuses on broadening Current Procedural Terminology (“CPT”) code coverage to increase patient access to advanced treatments and enable higher provider reimbursement rates.
  • “Our focus extends beyond merely seeking expanded insurance coverage; we're advocating for the enhancement of patient quality of life and ensuring access to essential dermatologic treatments," stated Dr. Dolev Rafaeli, Vice Chairman and Chief Executive Officer of STRATA.
  • Over the past two months, as part of this advocacy initiative STRATA has sent over 1,000 legislative support letters to congressional and senate delegates on behalf of its patients.
  • Phototherapy has been the cornerstone of therapy for decades and remains an indispensable part of current therapy.

STRATA Skin Sciences Announces Expansion of Distribution Agreement with Kosmo Meditech

Retrieved on: 
金曜日, 12月 29, 2023
Marketing, Growth, Partnership, SSKN, STRATA

HORSHAM, Pa., Dec. 29, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the expansion of a direct distribution agreement with Kosmo Meditech (“Kosmo”), which is now assigned to Kosmo's corporate parent, Cutech, Inc., effective as of January 1, 2024, for a combination of direct capital sales and direct recurring revenue sales in Korea.

Key Points: 
  • HORSHAM, Pa., Dec. 29, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the expansion of a direct distribution agreement with Kosmo Meditech (“Kosmo”), which is now assigned to Kosmo's corporate parent, Cutech, Inc., effective as of January 1, 2024, for a combination of direct capital sales and direct recurring revenue sales in Korea.
  • The key highlights of this amendment, which reinforce STRATA's commitment to innovation and customer satisfaction, include:
    Extended term through December 31, 2026, ensuring a prolonged and stable partnership
    Established defined annual and quarterly performance-based purchase requirements, including STRATA becoming sole provider of gas and consumables, securing a consistent demand for STRATA’s products, providing a reliable forecast for production and inventory management, and ensuring stronger top-line revenue
    “This agreement not only signifies the strength and growth of the partnership between STRATA and Kosmo but also reinforces STRATA's dedication to upholding the highest standards in product and service offerings for dermatological treatments worldwide,” stated Dr. Dolev Rafaeli, President and Chief Executive Officer of STRATA.
  • “Korea continues to present a significant opportunity for us, leveraging Kosmo’s extensive in-country distribution network.
  • This ongoing collaboration allows us to provide our customers with innovative therapeutic solutions while ensuring a framework for sustainable growth and market leadership.”

STRATA Skin Science Announces Strengthening of Leadership Team

Retrieved on: 
月曜日, 12月 4, 2023
Marketing, Business, Research, Acquisition, Business administration, Electronics, Cornell University, Master of Business Administration, Knowledge, Engineering, STRATA, Growth, Publication, SSKN, Pleasure, Management

HORSHAM, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the promotion of Shmuel Gov to Chief Operating Officer. The Company has also hired Dr. Amandeep Kaur as Vice President of Marketing and Business Growth.

Key Points: 
  • His outstanding leadership, strategic insight, and continued commitment to our mission make him the ideal choice to drive our operational excellence.
  • Together, we will reach new heights and achieve success in our shared journey,” expressed Shmuel Gov, Chief Operating Officer of STRATA.
  • Additionally, Dr. Amandeep Kaur has rejoined STRATA and brings years of experience and background in business development, marketing, and technology.
  • Her close ties with the clinical and research community and her experience as a business development leader will help STRATA accomplish its near-term turn-around goals.”

10 Barrel Brewing Co. Launches Revitalized Hopburst IPA Collection

Retrieved on: 
木曜日, 11月 30, 2023
Cloud, Friends, Cannabis, Sauter, MOSAIC, Haze, Acquisition, ABV, Marketing, Herbal, Beer, TLRY, STRATA, Magic, TSX, India pale ale, BRAVO, Citrus, Double

BEND, Ore., Nov. 30, 2023 (GLOBE NEWSWIRE) -- 10 Barrel Brewing Co (“10 Barrel”), a subsidiary of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), proudly unveils the reimagined HopBurst Family of IPAs.

Key Points: 
  • BEND, Ore., Nov. 30, 2023 (GLOBE NEWSWIRE) -- 10 Barrel Brewing Co (“10 Barrel”), a subsidiary of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), proudly unveils the reimagined HopBurst Family of IPAs.
  • Since its inception, 10 Barrel has continuously evolved, mirroring the dynamic spirit of Oregon's craft beer scene.
  • Combining artistic expression with brewing artistry, 10 Barrel has collaborated with artist Kyle Sauter, renowned for his work with other local industry giants.
  • Hops: STRATA • EL DORADO • SIMCOE HOPS
    The HopBurst IPA Trio is currently sold in Oregon, Washington, Idaho, and California at select retailers.

STRATA Skin Sciences Reports Third Quarter 2023 Revenue

Retrieved on: 
火曜日, 11月 14, 2023
Webcast, EBITDA, ID, Three Months, SSKN, Strata Skin Sciences, International, Depreciation, Laser, Marketing, Advertising, Financial Accounting Standards Board, GAAP, Partnership, Growth, Dermatology, Toys "R" Us Canada, STRATA, Video game, Cryptocurrency, Bank

Third Quarter 2023 and Recent Business Highlights:

Key Points: 
  • Third Quarter 2023 and Recent Business Highlights:
    Total Revenues were $8.9 million compared to $9.4 million for the third quarter of 2022, a total decrease of 6.0%.
  • “I am pleased to have rejoined the STRATA Skin Sciences team,” commented Dr. Dolev Rafaeli, Vice-Chairman, and Chief Executive Officer.
  • Global recurring revenues for the third quarter of 2023 were $5.3 million, compared to global recurring revenues of $5.8 million for the third quarter of 2022.
  • Other expense for the third quarter of 2023 was $0.4 million, compared to $0.2 million for the third quarter of 2022.

STRATA Skin Science Announces Leadership Change

Retrieved on: 
月曜日, 10月 30, 2023
Psoriasis, Vitiligo, STRATA, Technion – Israel Institute of Technology, Bachelor of Science, Intellectual property, Doctor of Philosophy, MBA, Growth, Acne, Marketing, Summa, Cornell University, SSKN, Master of Science, Patient, Management

HORSHAM, Pa., Oct. 30, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that the Board of Directors and Bob Moccia have mutually agreed that Mr. Moccia will step down as the Company’s Chief Executive Officer (CEO) and member of the Board, as of October 30, 2023. Dr. Dolev Rafaeli has been named the new Vice-Chairman, President and Chief Executive Officer.

Key Points: 
  • Dr. Dolev Rafaeli has been named the new Vice-Chairman, President and Chief Executive Officer.
  • Additionally, from 2006 to 2017, he served as the President and CEO of Radiancy Inc., a subsidiary of PhotoMedex.
  • “On behalf of the Board, I would like to thank Bob Moccia for his dedicated leadership and invaluable contributions during his time at the helm of STRATA,” stated Dr. Uri Geiger, Chairman of the Board.
  • I take great pride in contributing to this outstanding team and look forward to STRATA’s future successes.”

STRATA Skin Sciences Reports Second Quarter 2023 Revenue

Retrieved on: 
水曜日, 8月 9, 2023
Advertising, International, Marketing, STRATA, Toys "R" Us Canada, Acne, GAAP, ID, Sale, Accounting, Trial of the century, Projection, SSKN, EBITDA, Webcast, Depreciation, Three Months, Rare-earth element, Video game, Bank

Second Quarter 2023 and Recent Business Highlights:

Key Points: 
  • Second Quarter 2023 and Recent Business Highlights:
    Revenues in the second quarter of 2023 were $8.3 million, compared to $9.1 million for the second quarter of 2022.
  • Regarding second quarter revenues, we expect international sales to improve sequentially, as anticipated sales during the second quarter have shifted into the second half of the year,” stated Bob Moccia, Chief Executive Officer of STRATA Skin Sciences.
  • Global recurring revenues for the second quarter of 2023 were $5.5 million, as compared to global recurring revenues of $5.6 million for the second quarter of 2022.
  • Other expense for the second quarter of 2023 was $1.2 million, as compared to $0.2 million for the second quarter of 2022.

STRATA Skin Sciences Appoints Dr. Uri Geiger to Chairman of its Board of Directors

Retrieved on: 
金曜日, 6月 30, 2023
Marketing, STRATA, Growth, SSKN, Management

HORSHAM, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the appointment of Dr. Uri Geiger as the Chairman of the Board of Directors.

Key Points: 
  • HORSHAM, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the appointment of Dr. Uri Geiger as the Chairman of the Board of Directors.
  • William Humphries will step down as Chairman and continue to serve on the Board, effective July 3, 2023, as he transitions into his role as Chief Executive Officer of Alcami Corporation.
  • “I’m honored to assume the role of Chairman at this pivotal moment in STRATA’s growth,” said Dr. Uri Geiger, Chairman of STRATA's Board of Directors.
  • “We are delighted to have Uri move into the position of Chairman of the Board of Directors,” stated Bob Moccia, Chief Executive Officer of STRATA Skin Sciences.

STRATA Skin Sciences Reports First Quarter 2023 Revenue

Retrieved on: 
月曜日, 5月 15, 2023
International, Marketing, STRATA, Toys "R" Us Canada, GAAP, Light, SSKN, EBITDA, Webcast, Three Months, Pharmaceutical industry, Video game, Bank

HORSHAM, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced financial results for the first quarter ended March 31, 2023.

Key Points: 
  • First Quarter 2023 and Recent Business Highlights:
    Revenue in the first quarter of 2023 was $7.6, compared to $7.0 million for the first quarter of 2022
    58 TheraClearX devices in the U.S. as of March 31, 2023
    Signed exclusive distribution agreement with Spectra Medical Pvt Ltd. for India
    “The first quarter of 2023 has been filled with commercial successes for STRATA, especially with the ramp-up of TheraClearX,” stated Bob Moccia, Chief Executive Officer of STRATA Skin Sciences.
  • Equipment revenues were $2.4 million for the first quarter of 2023, as compared to $2.0 million for the first quarter of 2022.
  • Other expense for the first quarter of 2023 was $0.3 million, as compared to $0.2 million for the first quarter of 2022.
  • The link to the webcast is available here: STRATA Skin Sciences Earnings Webcast and will be archived for future reference.